Epithalon vs FOXO4-DRI: Two Opposite Ideas About Ageing Cells, Compared

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee, and Pepti is cash-pay and does not bill insurance. Current pricing always lives on each product page.

The real difference is the hypothesis

Neither is "stronger," and no study has compared them. They answer different questions about why tissue ages. Epithalon's telomerase story is about keeping cells dividing; that is also, as the FDA pointed out in July 2026, the mechanism by which cells escape senescence. FOXO4-DRI's story is that senescent cells are the problem, and that removing them, rather than keeping them going, improves the tissue around them. Both hypotheses meet cancer biology from opposite sides, which is why a cancer history matters for both.

Identical vials, different evidence

By coincidence, Pepti's vials are the same strength and drawn the same way, so each dose delivers 0.5 mg of either peptide. That does not make them interchangeable. Epithalon has about thirty years of Russian research behind it, much of it with the extract and from one network. FOXO4-DRI has about nine years of well-defined mechanism work, all in mice and cells.

A committee vote is a recommendation, not a decision. FOXO4-DRI has simply not been through the process; the FDA notes that substances nominated on or after 7 January 2025 are no longer placed in the interim categories. Both remain legal to prescribe and dispense as compounded medications. Compounded medications are not FDA approved, and neither Epithalon nor FOXO4-DRI is an FDA-approved drug. Are peptides FDA approved explains the difference.

Both are injected under the skin (subcutaneously) into the abdomen or thigh, rotating sites, with weekends off. In both cases the schedule is a prescribing convention, not a trial result. The Epithalon protocols in the Russian work were intermittent courses; the FOXO4-DRI mouse work used a short course of intraperitoneal injections, not weeks of subcutaneous dosing. You do not need to calculate anything: your directions are printed on the vial, and your physician sets them after reviewing your intake. Refills run every 28 days, one vial per fill. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. The Epithalon unit chart is in Epithalon dosage.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Epithalon. Generally described as well tolerated in the animal work and in the Russian clinical reports, which give no details. Reported clinically: injection-site redness, mild soreness, occasional bruising, and some early drowsiness or vivid dreams. The FDA's July 2026 review found no human pharmacokinetic data, no clinical safety study and no adverse-event reports, which is an absence of data, not evidence of safety. Its specific concern was continuous, long-term telomerase activation.

FOXO4-DRI. The safety record is a mouse record: the 2017 paper reported it well tolerated at the doses used. Reported clinically: mostly injection-site reactions. Its unusual chemistry, D-amino acids plus a cell-penetrating tail, makes immune reactions a theoretical concern that has not been studied in people. A 2023 Circulation study reported that removing senescent cells in mouse pulmonary vessels worsened pulmonary hypertension, a class finding in mice that anyone with lung disease should raise.

For both, there is no established interaction list. Stop and contact your physician for any reaction that is severe or spreading. Swelling of the face, lips or throat, a widespread rash or difficulty breathing needs emergency care first: call 911, then tell your care team.

Neither has been shown in a human trial to slow ageing or improve any outcome a person would notice. Epithalon has telomerase findings in cultured cells from two independent labs, rodent lifespan work, a melatonin effect in old monkeys, and a human record that is small, old, open-label and mostly with the parent extract. FOXO4-DRI has a precisely defined mechanism, consistent mouse and cell studies, and no human data at all. Any provider claiming either reverses ageing in people is describing something that has not been studied. The evidence in more detail is in Epithalon benefits.

Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes both in every state except Oklahoma, plus DC Step by step: how to get Epithalon prescribed online.